The mitogen-activated protein kinase phosphatase Vaccinia H1-related protein inhibits apoptosis in prostate cancer cells and is overexpressed in prostate cancer

Cancer Research

Volumn 68, Issue 22, 2008, Pages 9255-9264

  Arnoldussen, Yke Jildouw ^a   Lorenzo, Petra I ^a   Pretorius, Maria E ^a,b   Wære, Håkon ^a,b   Risberg, Bjørn ^a,b   Mælandsmo, Gunhild M ^b   Danielsen, Håvard E ^a,b   Saatcioglu, Fahri ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CELL PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; PHORBOL 13 ACETATE 12 MYRISTATE; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; THAPSIGARGIN; UNCLASSIFIED DRUG; VACCINIA H1 RELATED PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL STRAIN COS7; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RNA INTERFERENCE; TUMOR XENOGRAFT; VACCINIA VIRUS;

ANDROGENS; APOPTOSIS; CELL LINE, TUMOR; DUAL SPECIFICITY PHOSPHATASE 1; DUAL SPECIFICITY PHOSPHATASE 3; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MAP KINASE SIGNALING SYSTEM; METRIBOLONE; PHOSPHORYLATION; PROSTATIC NEOPLASMS; RNA, MESSENGER; TETRADECANOYLPHORBOL ACETATE; THAPSIGARGIN;

EID: 56449110281     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-1224     Document Type: Article

References (50)

1. Dehm SM, Tindall DJ. Molecular regulation of androgen action in prostate cancer. J Cell Biochem 2006;99:333-44.
2. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004;25:276-308.
3. Kaarbo M, Klokk TI, Saatcioglu F. Androgen signaling and its interactions with other signaling pathways in prostate cancer. Bioessays 2007;29:1227-38.
4. Mercader M, Sengupta S, Bodner BK, et al. Early effects of pharmacological androgen deprivation in human prostate cancer. BJU Int 2007;99:60-7.
5. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45.
6. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001;410:37-40.
7. Engelberg D. Stress-activated protein kinases-tumor suppressors or tumor initiators? Semin Cancer Biol 2004;14:271-82.
8. Wada T, Penninger JM. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 2004;23:2838-49.
9. Owens DM, Keyse SM. Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene 2007;26:3203-13.
10. Alonso A, Sasin J, Bottini N, et al. Protein tyrosine phosphatases in the human genome. Cell 2004;117:699-711.
11. Farooq A, Zhou MM. Structure and regulation of MAPK phosphatases. Cell Signal 2004;16:769-79.
12. Ishibashi T, Bottaro DP, Chan A, Miki T, Aaronson SA. Expression cloning of a human dual-specificity phosphatase. Proc Natl Acad Sci U S A 1992;89:12170-4.
13. Alonso A, Saxena M, Williams S, Mustelin T. Inhibitory role for dual specificity phosphatase VHR in T cell antigen receptor and CD28-induced Erk and Jnk activation. J Biol Chem 2001;276:4766-71.
14. Todd JL, Rigas JD, Rafty LA, Denu JM. Dual-specificity protein tyrosine phosphatase VHR downregulates c-Jun N-terminal kinase ( JNK). Oncogene 2002;21:2573-83.
15. Todd JL, Tanner KG, Denu JM. Extracellular regulated kinases (ERK) 1 and ERK2 are authentic substrates for the dual-specificity protein-tyrosine phosphatase VHR. A novel role in down-regulating the ERK pathway. J Biol Chem 1999;274:13271-80.
16. Rahmouni S, Cerignoli F, Alonso A, et al. Loss of the VHR dual-specific phosphatase causes cell-cycle arrest and senescence. Nat Cell Biol 2006;8:524-31.
17. Engedal N, Korkmaz CG, Saatcioglu F. C-Jun N-terminal kinase is required for phorbol ester- and thapsigargin-induced apoptosis in the androgen responsive prostate cancer cell line LNCaP. Oncogene 2002;21:1017-27.
18. Lorenzo PI, Saatcioglu F. Inhibition of apoptosis in prostate cancer cells by androgens is mediated through downregulation of c-Jun N-terminal kinase activation. Neoplasia 2008;10:418-28.
19. Xi Z, Klokk TI, Korkmaz K, et al. Kallikrein 4 is a predominantly nuclear protein and is overexpressed in prostate cancer. Cancer Res 2004;64:2365-70.
20. Nagabhushan M, Miller CM, Pretlow TP, et al. CWR22: the first human prostate cancer xenograft withs trongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res 1996;56:3042-6.
21. Zheng C, Xiang J, Hunter T, Lin A. The JNKK2-1 fusion protein acts as a constitutively active c-Jun kinase that stimulates c-Jun transcription activity. J Biol Chem 1999;274:28966-71.
22. Klokk TI, Kilander A, Xi Z, et al. Kallikrein 4 is a proliferative factor that is overexpressed in prostate cancer. Cancer Res 2007;67:5221-30.
23. Zhou JY, Liu Y, Wu GS. The role of mitogen-activated protein kinase phosphatase-1 in oxidative damage-induced cell death. Cancer Res 2006;66:4888-94.
24. Mandl M, Slack DN, Keyse SM. Specific inactivation and nuclear anchoring of extracellular signal-regulated kinase 2 by the inducible dual-specificity protein phosphatase DUSP5. Mol Cell Biol 2005;25:1830-45.
25. Willoughby EA, Perkins GR, Collins MK, Whitmarsh AJ. The JNK-interacting protein-1 scaffold protein targets MAPK phosphatase-7 to dephosphorylate JNK. J Biol Chem 2003;278:10731-6.
26. Smitherman AB, Gregory CW, Mohler JL. Apoptosis levels increase after castration in the CWR22 human prostate cancer xenograft. Prostate 2003;57:24-31.
27. Alonso A, Rahmouni S, Williams S, et al. Tyrosine phosphorylation of VHR phosphatase by ZAP-70. Nature Immunol 2003;4:44-8.
28. Lorenzo PI, Arnoldussen YJ, Saatcioglu F. Molecular mechanisms of apoptosis in prostate cancer. Crit Rev Oncogen 2007;13:1-38.
29. Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004;6:1-6.
30. Gavrielides MV, Gonzalez-Guerrico AM, Riobo NA, Kazanietz MG. Androgens regulate protein kinase Cδ transcription and modulate its apoptotic function in prostate cancer cells. Cancer Res 2006;66:11792-801.
31. Altuwaijri S, Lin HK, Chuang KH, et al. Interruption of nuclear factor κB signaling by the androgen receptor facilitates 12-O- tetradecanoylphorbolacetate-induced apoptosis in androgen-sensitive prostate cancer LNCaP cells. Cancer Res 2003;63:7106-12.
32. Tepper CG, Boucher DL, Ryan PE, et al. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 2002;62:6606-14.
33. Li L, Ittmann MM, Ayala G, et al. The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis 2005;8:108-18.
34. Kamata H, Honda S, Maeda S, Chang L, Hirata H, Karin M. Reactive oxygen species promote TNFα-induced deathand sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 2005;120:649-61.
35. Pinthus JH, Bryskin I, Trachtenberg J, et al. Androgen induces adaptation to oxidative stress in prostate cancer: implications for treatment withr adiation therapy. Neoplasia 2007;9:68-80.
36. Yu W, Imoto I, Inoue J, Onda M, Emi M, Inazawa J. A novel amplification target, DUSP26, promotes anaplastic thyroid cancer cell growth by inhibiting p38 MAPK activity. Oncogene 2007;26:1178-87.
37. Denkert C, Schmitt WD, Berger S, et al. Expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) in primary human ovarian carcinoma. Int J Cancer 2002;102:507-13.
38. Wang HY, Cheng Z, Malbon CC. Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer. Cancer Lett 2003;191:229-37.
39. Liao Q, Guo J, Kleeff J, et al. Down-regulation of the dual-specificity phosphatase MKP-1 suppresses tumor-igenicity of pancreatic cancer cells. Gastroenterology 2003;124:1830-45.
40. Wang Z, Xu J, Zhou JY, Liu Y, Wu GS. Mitogen-Activated Protein Kinase Phosphatase-1 Is Required for Cisplatin Resistance. Cancer Res 2006;66:8870-7.
41. Sekine Y, Ikeda O, Hayakawa Y, et al. DUSP22/LMW-DSP2 regulates estrogen receptor-α-mediated signaling through dephosphorylation of Ser-118. Oncogene 2007;26:6038-49.
42. Henkens R, Delvenne P, Arafa M, et al. Cervix carcinoma is associated withan up-regulation and nuclear localization of the dual-specificity protein phosphatase VHR. BMC Cancer 2008;8:147.
43. Srikanth S, Franklin CC, Duke RC, Kraft RS. Human DU145 prostate cancer cells overexpressing mitogen-activated protein kinase phosphatase-1 are resistant to Fas ligand-induced mitochondrial perturbations and cellular apoptosis. Mol Cell Biochem 1999;199:169-78.
44. Chen L, He HY, Li HM, et al. ERK1/2 and p38 pathways are required for P2Y receptor-mediated prostate cancer invasion. Cancer Lett 2004;215:239-47.
45. Magi-Galluzzi C, Mishra R, Fiorentino M, et al. Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis. Lab Invest 1997;76:37-51.
46. Magi-Galluzzi C, Montironi R, Cangi MG, Wishnow K, Loda M. Mitogen-activated protein kinases and apoptosis in PIN. Virchows Arch 1998;432:407-13.
47. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006;127:679-95.
48. Su AI, Cooke MP, Ching KA, et al. Large-scale analysis of the human and mouse transcriptomes. Proc Natl Acad Sci U S A 2002;99:4465-70.
49. Welsh JB, Sapinoso LM, Su AI, et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 2001;61:5974-8.
50. Tomlins SA, Mehra R, Rhodes DR, et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007;39:41-51.